Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis - PubMed

Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis - PubMed

Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis

Arno C Hessels 1, Jan Stephan F Sanders 2, Abraham Rutgers 3, Coen A Stegeman 2

Affiliations 

• PMID: 32683418
 
• DOI: 10.1038/s41397-020-0176-z

Abstract

The introduction of immunosuppressive therapy for ANCA-associated vasculitis (AAV) has greatly improved outcomes, though patients now accumulate damage from vasculitis activity and adverse effects of treatment. Prediction of treatment outcomes using gene variants might help reduce this damage by allowing for personalized treatment. Several studies have studied genetic polymorphisms in relation to treatment outcomes of AAV. This review gives an overview of these studies, discussing both gene polymorphisms associated with inflammatory pathways (potentially influencing disease outcomes such as activity, severity, and relapse risk) and pharmacogenetics (potentially influencing drug metabolism and/or drug response). Subsequently, potential benefits of testing genetic variants for AAV and the steps needed for its implementation in clinical practice are discussed. The conclusion of this review is that measurement of most polymorphisms is currently not indicated in clinical practice.

Similar articles

• Genetic variants in ANCA-associated vasculitis: a meta-analysis.

  Rahmattulla C, Mooyaart AL, van Hooven D, Schoones JW, Bruijn JA, Dekkers OM; European Vasculitis Genetics Consortium, Bajema IM.Ann Rheum Dis. 2016 Sep;75(9):1687-92. doi: 10.1136/annrheumdis-2015-207601. Epub 2015 Oct 6.PMID: 26443607
• Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

  Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA; BREVAS Study Collaborators.Arthritis Rheumatol. 2019 Jun;71(6):952-963. doi: 10.1002/art.40802. Epub 2019 Apr 16.PMID: 30666823 Free PMC article. Clinical Trial.
• Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

  Chen M, Gao Y, Guo XH, Zhao MH.Nat Rev Nephrol. 2012 Jun 5;8(8):476-83. doi: 10.1038/nrneph.2012.108.PMID: 22664738 Review.
• Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.

  Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.Nephrol Dial Transplant. 2016 Sep;31(9):1453-9. doi: 10.1093/ndt/gfw211. Epub 2016 May 30.PMID: 27242368 Clinical Trial.
• Treatment Strategies in ANCA-Associated Vasculitis.

  Emejuaiwe N.Curr Rheumatol Rep. 2019 May 23;21(7):33. doi: 10.1007/s11926-019-0835-8.PMID: 31123922 Review.